- Legend Biotech USA, Inc. (Piscataway, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... with other lab duties. The ideal candidate has experience in immune-oncology and/or CAR natural killer (NK) and/or gamma-delta (gd) T cells and is willing to embrace… more
- Merck & Co. (Rahway, NJ)
- …copyright compliance Familiarity with the application of semantic technologies, Natural Language Processing (NLP), Machine Learning (ML) or Artificial Intelligence ... (AI) Experience with the SDLC (system development lifecycle) NOTICE FOR INTERNAL APPLICANTS In accordance with Managers' Policy - Job Posting and Employee Placement, all employees subject to this policy are required to have a minimum of twelve (12) months of… more
- Merck & Co. (Rahway, NJ)
- …as cell line engineering to build reporter gene assays, flow cytometry, natural killer (NK) cell assays for cytotoxicity, and/or effector function assays.Strong ... knowledge and statistical skills for interpretation of potency data in context of broader process and product development, control strategy, and specifications-setting.-Deep working knowledge of regulatory guidance and quality standards, with experience… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- BioAgilytix (Durham, NC)
- …hold an operationally efficient mindset, where project management skills are boosted by natural people skills. You are self-motivated and inspire others in a way ... that is courteous and respectful, all while balancing firm project boundaries. If you are energized by providing great sponsor experience in a deadline-driven environment, then you'll be right at home here at BioAgilytix.Essential ResponsibilitiesPartner with… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Piscataway, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Eisai, Inc (Nutley, NJ)
- …economic projects including but not limited to: advanced models ( natural history, microsimulation, Markov, compartmental, among others); applied health economic ... models (cost-utility, cost-effectiveness, budget-impact, burden of illness, etc.) as well as the potential for observational health economic studies (prospective or retrospective study of cost and/or outcomes).Conduct systematic literature reviews, comparative… more
- Daiichi Sankyo, Inc. (Basking Ridge, NJ)
- …and machine learning (ML) techniques. Experience with Gen AI, deep learning, natural language processing (NLP), and predictive modeling is a plus. Travel:Ability to ... travel up to 5% Occasional travel for meetings and seminarsDaiichi Sankyo, Inc. is an equal opportunity/affirmative action employer. Qualified applicants will receive consideration for employment without regard to sex, gender identity, sexual orientation,… more
- Legend Biotech USA, Inc. (Piscataway, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Piscataway, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Legend Biotech entered into a global ... collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel) in 2017. Our strategic partnership is designed to combine the strengths and expertise of… more
